动物造模,妊高症大鼠模型 z-bio 2022-03-23 494

　　Objective To determine the therapeutic effect of trigonelline in early pregnancy in rats with PE induced by the nitric oxide synthase antagonist N-nitro-1-arginine methyl ester (LNAME).

　　Methods On the 0th day of pregnancy, 28 Sprague-Dawley (SD) rats were randomly divided into 4 groups: the pregnant control group, the LNAME-induced PE group, and the prophylactic trigonelline-administered low-dose and high-dose groups; measurement The blood pressure and proteinuria of pregnant mice were collected, the endothelial function of pregnant mice was evaluated by femoral artery ultrasound, the expressions of inflammatory factors and endothelial-related factors were detected by ELISA, and the placenta and kidney of pregnant mice were finally harvested for immunohistochemical analysis. -qPCR) and Western blotting to analyze the status of inflammation-related pathways.

　　Results Prophylactic administration of low-dose and high-dose trigonelline ameliorated LNAME-induced hypertension, proteinuria, weight loss, fetal growth restriction and blood flow-mediated dilatation in pregnant rats, and trigonelline might be through the pathway of IκBα/ NF-κB balances endothelial-related factors and attenuates inflammatory activation in placental and renal tissues.

　　Conclusion Trigonelline prophylactic use in LNAME-induced PE-like rat model can alleviate PE symptoms, promote fetal growth, protect endothelial function and reduce inflammation.